Establishing contemporary trends in hepatitis B sero-epidemiology in an Indigenous population

Jane Davies, Shu Qin Li, Steven Y. Tong, Rob W. Baird, Miles Beaman, Geoff Higgins, Benjamin C. Cowie, John R. Condon, Joshua S. Davis

    Research output: Contribution to journalArticleResearchpeer-review

    13 Downloads (Pure)

    Abstract

    Background: Indigenous populations globally are disproportionately affected by chronic hepatitis B virus (HBV) infection however contemporary sero-prevalence data are often absent. In the Indigenous population of the Northern Territory (NT) of Australia the unique C4 sub-genotype of HBV universally circulates. There are no studies of the sero-prevalence, nor the impact of the vaccination program (which has a serotype mismatch compared to C4), at a population-wide level. 

    Methods: We examined all available HBV serology results obtained from the three main laboratories serving NT residents between 1991 and 2011. Data were linked with a NT government database to determine Indigenous status and the most recent test results for each individual were extracted as a cross-sectional database including 88,112 unique individuals. The primary aim was to obtain a contemporary estimate of HBsAg positivity for the NT by Indigenous status. 

    Results: Based on all tests from 2007–2011 (35,633 individuals), hepatitis B surface antigen (HBsAg) positivity was 340% (95%CI 319–361), being higher in Indigenous (608% [565%-653%]) than non-Indigenous (156%[138%-176%]) Australians, p<00001. Birth cohort analysis showed HBsAg positivity fell over time for Indigenous people, with this decrease commencing prior to universal infant vaccination (which commenced in 1990), with an ongoing but slower rate of decline since 1990, (023% decrease per year versus 017%). 

    Conclusions: HBsAg positivity is high in the NT, particularly in the Indigenous population. HBsAg positivity has fallen over time but a substantial part of this decrease is due to factors other than the universal vaccination program.

    Original languageEnglish
    Article numbere0184082
    Pages (from-to)1-13
    Number of pages13
    JournalPLoS One
    Volume12
    Issue number9
    DOIs
    Publication statusPublished - 8 Sep 2017

    Fingerprint

    Northern Territory
    Epidemiology
    hepatitis B
    serological surveys
    Hepatitis B Surface Antigens
    Hepatitis B
    Population Groups
    Hepatitis B virus
    Viruses
    Vaccination
    vaccination
    seroprevalence
    Databases
    chronic hepatitis B
    indigenous peoples
    Chronic Hepatitis B
    Virus Diseases
    Serology
    serotypes
    Cohort Studies

    Cite this

    Davies, Jane ; Li, Shu Qin ; Tong, Steven Y. ; Baird, Rob W. ; Beaman, Miles ; Higgins, Geoff ; Cowie, Benjamin C. ; Condon, John R. ; Davis, Joshua S. / Establishing contemporary trends in hepatitis B sero-epidemiology in an Indigenous population. In: PLoS One. 2017 ; Vol. 12, No. 9. pp. 1-13.
    @article{4af9dc22743f4fb4978ce22991e58695,
    title = "Establishing contemporary trends in hepatitis B sero-epidemiology in an Indigenous population",
    abstract = "Background: Indigenous populations globally are disproportionately affected by chronic hepatitis B virus (HBV) infection however contemporary sero-prevalence data are often absent. In the Indigenous population of the Northern Territory (NT) of Australia the unique C4 sub-genotype of HBV universally circulates. There are no studies of the sero-prevalence, nor the impact of the vaccination program (which has a serotype mismatch compared to C4), at a population-wide level. Methods: We examined all available HBV serology results obtained from the three main laboratories serving NT residents between 1991 and 2011. Data were linked with a NT government database to determine Indigenous status and the most recent test results for each individual were extracted as a cross-sectional database including 88,112 unique individuals. The primary aim was to obtain a contemporary estimate of HBsAg positivity for the NT by Indigenous status. Results: Based on all tests from 2007–2011 (35,633 individuals), hepatitis B surface antigen (HBsAg) positivity was 340{\%} (95{\%}CI 319–361), being higher in Indigenous (608{\%} [565{\%}-653{\%}]) than non-Indigenous (156{\%}[138{\%}-176{\%}]) Australians, p<00001. Birth cohort analysis showed HBsAg positivity fell over time for Indigenous people, with this decrease commencing prior to universal infant vaccination (which commenced in 1990), with an ongoing but slower rate of decline since 1990, (023{\%} decrease per year versus 017{\%}). Conclusions: HBsAg positivity is high in the NT, particularly in the Indigenous population. HBsAg positivity has fallen over time but a substantial part of this decrease is due to factors other than the universal vaccination program.",
    author = "Jane Davies and Li, {Shu Qin} and Tong, {Steven Y.} and Baird, {Rob W.} and Miles Beaman and Geoff Higgins and Cowie, {Benjamin C.} and Condon, {John R.} and Davis, {Joshua S.}",
    year = "2017",
    month = "9",
    day = "8",
    doi = "10.1371/journal.pone.0184082",
    language = "English",
    volume = "12",
    pages = "1--13",
    journal = "PLoS One",
    issn = "1932-6203",
    publisher = "Public Library of Science (PLoS)",
    number = "9",

    }

    Establishing contemporary trends in hepatitis B sero-epidemiology in an Indigenous population. / Davies, Jane; Li, Shu Qin; Tong, Steven Y.; Baird, Rob W.; Beaman, Miles; Higgins, Geoff; Cowie, Benjamin C.; Condon, John R.; Davis, Joshua S.

    In: PLoS One, Vol. 12, No. 9, e0184082, 08.09.2017, p. 1-13.

    Research output: Contribution to journalArticleResearchpeer-review

    TY - JOUR

    T1 - Establishing contemporary trends in hepatitis B sero-epidemiology in an Indigenous population

    AU - Davies, Jane

    AU - Li, Shu Qin

    AU - Tong, Steven Y.

    AU - Baird, Rob W.

    AU - Beaman, Miles

    AU - Higgins, Geoff

    AU - Cowie, Benjamin C.

    AU - Condon, John R.

    AU - Davis, Joshua S.

    PY - 2017/9/8

    Y1 - 2017/9/8

    N2 - Background: Indigenous populations globally are disproportionately affected by chronic hepatitis B virus (HBV) infection however contemporary sero-prevalence data are often absent. In the Indigenous population of the Northern Territory (NT) of Australia the unique C4 sub-genotype of HBV universally circulates. There are no studies of the sero-prevalence, nor the impact of the vaccination program (which has a serotype mismatch compared to C4), at a population-wide level. Methods: We examined all available HBV serology results obtained from the three main laboratories serving NT residents between 1991 and 2011. Data were linked with a NT government database to determine Indigenous status and the most recent test results for each individual were extracted as a cross-sectional database including 88,112 unique individuals. The primary aim was to obtain a contemporary estimate of HBsAg positivity for the NT by Indigenous status. Results: Based on all tests from 2007–2011 (35,633 individuals), hepatitis B surface antigen (HBsAg) positivity was 340% (95%CI 319–361), being higher in Indigenous (608% [565%-653%]) than non-Indigenous (156%[138%-176%]) Australians, p<00001. Birth cohort analysis showed HBsAg positivity fell over time for Indigenous people, with this decrease commencing prior to universal infant vaccination (which commenced in 1990), with an ongoing but slower rate of decline since 1990, (023% decrease per year versus 017%). Conclusions: HBsAg positivity is high in the NT, particularly in the Indigenous population. HBsAg positivity has fallen over time but a substantial part of this decrease is due to factors other than the universal vaccination program.

    AB - Background: Indigenous populations globally are disproportionately affected by chronic hepatitis B virus (HBV) infection however contemporary sero-prevalence data are often absent. In the Indigenous population of the Northern Territory (NT) of Australia the unique C4 sub-genotype of HBV universally circulates. There are no studies of the sero-prevalence, nor the impact of the vaccination program (which has a serotype mismatch compared to C4), at a population-wide level. Methods: We examined all available HBV serology results obtained from the three main laboratories serving NT residents between 1991 and 2011. Data were linked with a NT government database to determine Indigenous status and the most recent test results for each individual were extracted as a cross-sectional database including 88,112 unique individuals. The primary aim was to obtain a contemporary estimate of HBsAg positivity for the NT by Indigenous status. Results: Based on all tests from 2007–2011 (35,633 individuals), hepatitis B surface antigen (HBsAg) positivity was 340% (95%CI 319–361), being higher in Indigenous (608% [565%-653%]) than non-Indigenous (156%[138%-176%]) Australians, p<00001. Birth cohort analysis showed HBsAg positivity fell over time for Indigenous people, with this decrease commencing prior to universal infant vaccination (which commenced in 1990), with an ongoing but slower rate of decline since 1990, (023% decrease per year versus 017%). Conclusions: HBsAg positivity is high in the NT, particularly in the Indigenous population. HBsAg positivity has fallen over time but a substantial part of this decrease is due to factors other than the universal vaccination program.

    UR - http://www.scopus.com/inward/record.url?scp=85029326386&partnerID=8YFLogxK

    U2 - 10.1371/journal.pone.0184082

    DO - 10.1371/journal.pone.0184082

    M3 - Article

    VL - 12

    SP - 1

    EP - 13

    JO - PLoS One

    JF - PLoS One

    SN - 1932-6203

    IS - 9

    M1 - e0184082

    ER -